MNPR PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

MNPR ▼ -0.15% at T+20d

LONG call ✗ call lost -0.15% · α vs SPY -12.89% · entry $54.10 → $54.02

Next anchor: T+60d in 4w

Last close $63.12 (close May 22) · +16.67% from $54.10 entry

Entry anchored
Mar 27, 12:53 PM ET
via Databento tick

T+1d

-1.50%

call -1.50% · α -1.14%

$53.29

settled 8w ago

T+5d

-0.78%

call -0.78% · α -4.64%

$53.68

settled 7w ago

T+20d

-0.15%

call -0.15% · α -12.89%

$54.02

settled 27d ago

T+60d

—

call — · α —

—

in 4w

Price Chart

Loading chart...

Executive Summary

Monopar Therapeutics reported its 2025 financial results, showing a reduced net loss and a strengthened balance sheet with $140.4 million in cash, supporting operations into 2027. The company highlighted progress toward a mid-2026 NDA submission for ALXN1840 in Wilson disease and ongoing development of its MNPR-101 radiopharmaceutical programs.

Key Financial Metrics

EPS

$-1.85

Actionable Insight

The improved financials and clear regulatory path for ALXN1840 suggest reduced near-term dilution risk and a potential catalyst in mid-2026 with the NDA filing. Traders should monitor upcoming EASL and AAN 2026 presentations for further clinical validation.

Key Facts

Cash, cash equivalents, and short-term investments totaled $140.4 million as of December 31, 2025.
Net loss for 2025 was $13.7 million ($1.85/share), down from $15.6 million ($4.11/share) in 2024.
Q4 2025 net loss was $5.2 million, significantly improved from $10.9 million in Q4 2024.
R&D expenses decreased to $9.9 million in 2025 from $13.0 million in 2024, primarily due to absence of one-time in-licensing costs.
G&A expenses rose to $6.8 million in 2025 from $3.2 million in 2024, driven by personnel and legal costs.
Company plans NDA submission for ALXN1840 in mid-2026 for Wilson disease, supported by positive long-term efficacy and safety data.
Financing activities in 2025 generated approximately $91.9 million from a public offering.

Financial Impact

Reduced annual net loss by $1.9 million and improved quarterly loss by $5.7 million YoY; raised $91.9 million in net proceeds, significantly extending cash runway.

netLosscashPositionR&DExpensesG&AExpenses

Risk Factors

Regulatory risk around FDA acceptance and approval of ALXN1840, despite planned NDA submission.
Increasing G&A expenses may signal rising overhead ahead of commercialization, potentially pressuring margins.

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3263989

6 reports for MNPR

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for MNPR — sortable, filterable
	Type				Now
May 19, 2026 4d ago	8-K BULLISH ★ 6/10	—	awaiting T+20	—	—
May 14, 2026 9d ago	8-K NEUTRAL ★ 4/10	$60.78 awaiting T+20	awaiting T+20	—	$63.12 (+3.85%)
May 14, 2026 9d ago	Press Release BULLISH ★ 6/10	$59.15 awaiting T+20	awaiting T+20	—	$63.12 (+6.71%)
Apr 20, 2026 4w ago	8-K BULLISH ★ 7/10	$54.70 $56.25	▲ +2.83%	▼ −1.37%	$63.12 (+15.39%)
Apr 19, 2026 4w ago	Press Release BULLISH ★ 8/10	$54.70 $56.25	▲ +2.83%	▼ −1.37%	$63.12 (+15.39%)
Mar 27, 2026 8w ago	Press Release BULLISH ★ 7/10	$54.10 $54.02	▼ −0.15%	▼ −12.89%	$63.12 (+16.67%)

US Market Status

Market Closed — Opens Tue (34h 51m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access